An update for Richter syndrome - new directions and developments.

@article{Eyre2017AnUF,
  title={An update for Richter syndrome - new directions and developments.},
  author={Toby A Eyre and Anna Schuh},
  journal={British journal of haematology},
  year={2017},
  volume={178 4},
  pages={508-520}
}
High-grade transformation of chronic lymphocytic leukaemia [Richter syndrome (RS)] is rare and represents a unique and uncommon clinical challenge. Clonally related diffuse large B cell type RS is a chemotherapy-resistant and devastating disease. Patients are typically elderly, immunosuppressed and present with a rapidly deteriorating performance status. Historical outcomes suggest a median overall survival of approximately 8 months. RS remains is an area of high unmet clinical need. The… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 83 references

Phase I - II study of oxaliplatin , fludarabine , cytarabine , and rituximab combination therapy in patients with Richter ’ s syndrome or fludarabinerefractory chronic lymphocytic leukemia

  • A. M. Tsimberidou, H. M. Kantarjian, M. J. Keating
  • Journal of Clinical Oncology
  • 2008
Highly Influential
2 Excerpts

Phase II study

  • A. M. Tsimberidou, S. M. O’Brien, +5 authors F. J. Giles
  • 2002
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…